HUM Stock Price Today (September 2026) — Humana Inc. Analysis & Key Metrics 2026-09-03
Humana Inc. (HUM) is trading at $406.52, up 1.38% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $418.61 (3.0% upside).
- Volatility remains elevated (18.07% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (26.20% YoY) alongside significant competitive pressures.
HUM Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Humana Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $37.23B
P/E Ratio
Forward P/E: 23.13
Revenue Growth
Year over Year
Analyst Target
+3.0% upside potential
Key Investor Questions About HUM
What investors need to know before buying
Based on current market data, HUM presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 67.63)
- Fundamentals say: Caution warranted (high leverage concerns)
HUM's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HUM investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $14.74B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, HUM stock traded between $163.11 and $428.88—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 18.07% annualized volatility and β=0.40, the stock exhibits low sensitivity to market moves—making HUM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
If Your Advantage Plan Ends December 31 and You Do Nothing, You Wake Up January 1 in Original Medicare With No Drug Coverage and No Medigap.
Humana's non-renewal letters are already in the mail, and the deadline to act is closer than most affected members realize. Missing it by even one day changes what coverage options remain available and how much they cost.
UnitedHealth Stock Recovered Before Its Margins Did
UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.
Is UnitedHealth Finally Turning the Corner After a Tough 2025?
UNH is showing signs of recovery as medical costs improve, Optum gains momentum and 2026 earnings guidance rises.
CVS Stock Has Left Its Peers Behind. Or Has It?
The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.
For 4 Years, The Villages’ Top Health Provider Allegedly Filed False Medicare Codes. The Bill Just Came Due: $541.5 Million.
A retirement community's top health provider quietly told the government it had been overbilling Medicare for years, then filed for bankruptcy before the consequences arrived. What happened next reshaped who owns the clinics, who absorbs the loss, and what federal prosecutors are targeting next.
Can Better Star Ratings and Margin Expansion Drive Humana (HUM) Higher?
Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]
Bill Ackman Backs Mark Cuban's Drug Pricing Model: These Healthcare Stocks Could Win—Or Lose
By endorsing Mark Cuban‘s proposals to make prescription drug pricing more transparent, Bill Ackman shifted the conversation from healthcare policy to something investors care about just as much: whether the traditional pharmacy benefit manager (PBM) model is facing a growing...
Johns Hopkins Health Plans taps interim CEO as it searches for successor
Daniel Chojnowski, JHHP’s current CFO, will provide stability so that the Baltimore-area insurer can recruit full-time for its next chief executive, the company said.
Humana (HUM) Names New Medical Chief On AI Push As Valuation Debate Builds
Humana (HUM) has drawn fresh attention after announcing that Shantanu Nundy, M.D., will become Chief Medical Officer on August 31, 2026, in a move that foregrounds technology, AI and clinical leadership. Humana’s appointment of a technology focused Chief Medical Officer comes as the stock trades at US$383.23. The share price return is up 5.32% over 30 days and 19.43% over 90 days, while the year-to-date share price return of 44.90% contrasts with a 3-year total shareholder return that has...
UNH Stock Gets Cheaper Only If The Margins Come Back
Consensus knocks a quarter off the health insurer's earnings multiple over two years, part of it measurement, and almost none of it from selling more coverage.
Explore More Analysis for HUM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Humana Inc.
Humana Inc. (HUM) is currently trading at $406.52. The RSI (14-day) is at 67.6, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $418.61 implies 3.0% upside from current levels. Volatility is low at 18.1% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Humana Inc. (HUM): The trailing P/E ratio is 38.72, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 23.13, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.22, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 2.54. Price-to-Sales is 0.34. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 23 analysts covering HUM, the consensus price target is $418.61. This represents a 3.0% upside from the current price of $406.52. The range spans from a low target of $280.00 to a high target of $513.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Humana Inc. (HUM) pays a dividend with a current yield of approximately 87.00%. The annualized dividend rate is $3.54 per share. The payout ratio is 33.5%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-06-26T00:00:00.000Z.
Key risks for Humana Inc. (HUM) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Humana Inc.'s (HUM) current debt and financial health profile: Total debt stands at $14.74B. The debt-to-equity ratio is 76.48, which is moderate and generally manageable for most companies. The current ratio is 1.74, indicating strong short-term liquidity. The quick ratio is 1.28. The company holds $23.87B in cash and equivalents. Free cash flow is positive at $1.94B, providing a cushion for debt servicing and shareholder returns.